enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
9.66
-0.34 (-3.40%)
At close: Mar 3, 2026, 4:00 PM EST
9.56
-0.10 (-1.04%)
After-hours: Mar 3, 2026, 4:25 PM EST
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 1980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | EFFECT | Notice of Effectiveness |
| Feb 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 19, 2026 | 10-K/A | [Amend] Annual report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 27, 2026 | SCHEDULE 13G | Filing |
| Jan 21, 2026 | 8-K | Current Report |
| Jan 21, 2026 | 8-K | Current Report |
| Dec 22, 2025 | 10-K | Annual Report |